IGF2BP1 and colorectal carcinoma: Previous studies have demonstrated that IGF2BP1 enhances WNT pathway signalling and that downregulation of IGF2BP1 can reduce the resistance of chemotherapy-resistant cancer cells that have an activated Wnt/β-catenin signalling pathway in colorectal carcinomas (CRC) [41, 42].